Press Releases :: BiomX, Inc. (PHGE)

Jul 14, 2025 9:00am EDT

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

Jul 08, 2025 8:30am EDT

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

May 19, 2025 10:02am EDT

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

May 15, 2025 6:30am EDT

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

May 08, 2025 7:00am EDT

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

Apr 01, 2025 6:30am EDT

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

Mar 31, 2025 6:30am EDT

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

Mar 25, 2025 6:30am EDT

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

Mar 19, 2025 12:35pm EDT

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Feb 26, 2025 8:00am EST

BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million

1
2
3
4
5
6
7
8
9
10
…14
Next

Investor Contact Information

Company

BiomX, Inc.
708 Quince Orchard Rd
Suite 205
Gaithersburg, MD 20878
USA
info@biomx.com

Investor Relations

Ben Cohen
benc@biomx.com